FDA Brief

Warning letters Drugs

FDA warning letter to

Herbsens Botanicals

High riskIssued Jun 30, 2022Posted Jul 5, 2022Center for Drug Evaluation and Research | CDER

Herbsens Botanicals marketed kratom capsules and powders as unapproved drugs to treat opioid addiction and other conditions.

What happened

FDA reviewed herbsenskratom.com in May 2022 and FTC reviewed it in June 2022. They found the site took orders for kratom capsule and powder products and made claims that the products treat opioid addiction and withdrawal, pain, depression, diabetes, high blood pressure, and other conditions. FDA determined the products are unapproved new drugs.

What FDA found

  1. The website claims kratom products treat or manage opioid addiction and withdrawal, pain, depression, diabetes, high blood pressure, and other conditions, making them drugs intended for disease treatment.

    FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)
  2. The products are 'new drugs' (not generally recognized as safe and effective for their claimed uses) under the FD&C Act.

    FD&C Act section 201(p), 21 U.S.C. 321(p)
  3. The company introduced the kratom products into interstate commerce without FDA approval.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
  4. The company advertised kratom as treating or curing addiction without competent and reliable scientific evidence.

    FTC Act, 15 U.S.C. §§ 41–57

What FDA wants

FDA asks the company to notify FDA in writing within 15 working days of the steps taken to correct the violations and prevent recurrence, with documentation, or explain why it believes the products are not violations. FTC separately asks for notice within 15 working days of actions taken to address its advertising concerns.

Who should pay attention

  • retailers and online sellers of kratom products
  • companies making addiction, pain, or other disease claims for botanical products
  • quality and regulatory teams that review website claims and product drug status

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk